3.7: PULSE WAVE VELOCITY IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS, MORTALITY AND DECLINE IN RENAL FUNCTION IN PATIENTS WITH TYPE 1 DIABETES

Tine Willum Hansen, Marie Frimodt-Møller, Simone Theilade, Nete Tofte, Tarun Veer Singh Ahluwalia, Peter Rossing

To cite this article: Tine Willum Hansen, Marie Frimodt-Møller, Simone Theilade, Nete Tofte, Tarun Veer Singh Ahluwalia, Peter Rossing (2018) 3.7: PULSE WAVE VELOCITY IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS, MORTALITY AND DECLINE IN RENAL FUNCTION IN PATIENTS WITH TYPE 1 DIABETES, Artery Research 24:C, 74–74, DOI: https://doi.org/10.1016/j.artres.2018.10.038

To link to this article: https://doi.org/10.1016/j.artres.2018.10.038

Published online: 7 December 2019

1Menzies Institute for Medical Research, Hobart, Australia  
2Menzies Institute for Medical Research, University of Tasmania, Australia  
3Menzies Institute for Medical Research of Tasmania, Australia  
4Institute of Biomedical Technologies, Australian National University, Australia  
5Department of Internal Medicine, St Antonius Hospital, Australia  
6Department of Medicine, National Yang-Ming University, Taiwan  
7Department of Medicine, National Yang-Ming University Taiwan, Taiwan  
8Department of Cardiology/Hypertension University Hospital of Bordeaux, France  
9Department of Cardiology, BMI Hospital Blackheath, UK  
10Institute of Cardiovascular Sciences, University College London, UK  
11Division of Cardiology, Seoul National University, South Korea  
12Institute of Cardiovascular Sciences, University College, Australia  
13Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark  
14Department of Critical Care Medicine, Flinders University, Australia  
15Department of Cardio-Renal Medicine and Hypertension, Nagoya City University, Australia  
16Clinical Research Unit, Italian Institute of Telemedicine, Italy  
17Department of Nephrology and Hypertension, Friedrich-Alexander University, Germany  
18Department of Cardiopneumology, Politecnico Institute of Coimbra, Portugal  
19Department of Medicine, University of Perugia, Italy  
20Green Lane Cardiovascular Service, University of Auckland, New Zealand  
21Division of Cardiology, University of North Carolina at Chapel Hill, USA  
22Department of Cardiovascular Medicine, Kumamoto University, Australia  
23Center for Health Surveillance and Prevention Medicine, Tokyo Medical University Hospital, Japan  
24School of Medicine, Shanghai Jiao Tong University, China  
25Cardiology Department, Klinikum Weis-Grieskirchen, UK  
26Department of Pulmonary Diseases, VU University Medical Center, the Netherlands  
27Department of Cardiovascular Medicine, Tokushima University Hospital, Japan  

Abstracts

3.6 BLOOD PRESSURE REDUCTION IS THE MAIN DETERMINANT OF THE DE-STIFFENING EFFECT OF ANTIHYPERTENSIVE TREATMENT: A META-REGRESSION ANALYSIS AND COMPARISON WITH ACUTE MODULATION OF TRANSMURAL PRESSURE

Andri Boguslavskiy 1, Benyu Jiang 2, Haotian Gu 3, Yao Lu 3, Marina Cecelja 2, Phil Chowienczyk 2
1Guy’s and St Thomas’ NHS Foundation Trust, London, UK  
2King’s College London, London, UK  
33rd Xiangya Hospital, Changsha, China

Background: Pulse wave velocity (PWV) is independent predictor of cardiovascular outcomes. Antihypertensive treatment reduces PWV, but it is unknown whether this results from an unloading of stiffer elements in the arterial wall or a structural change in the wall.

Methods: To distinguish between these effects we performed a systematic review and meta-regression analysis of effects of different drug classes and durations of antihypertensive treatment on the relationship between reduction in PWV and that in mean arterial pressure (MAP). We compared this to the variation in PWV during an acute modulation of aortic transmural pressure (TMP) by respiratory manoeuvres, simulating a change in MAP in patients with essential hypertension.

Results: We identified 99 trials on 6,703 hypertensive individuals in total (average age and treatment duration were 56 ± 9.4 years and 21.6 ± 17.9 weeks, respectively). Reduction in PWV was strongly associated with that in MAP, PWV falling by 0.7 m/s per 10 mmHg fall in MAP (95% CI 0.5 – 0.86 m/s, p < 0.001). However, reduction in PWV was independent of drug class or duration of treatment. Change in PWV during respiratory manoeuvres was related to TMP with a similar relation to that observed in the meta-regression analysis: 0.94 m/s per 10 mmHg change in TMP (95% CI 0.34 – 1.54 m/s, p < 0.001).

Conclusion: Antihypertensive treatment reduces PWV mainly by an unloading effect on the arterial wall, at least over the short term. There is little evidence for a treatment-specific effect. It may be possible to predict effects of antihypertensive treatment on reduction of PWV and pulse pressure by modulating transmural pressure.

3.7 PULSE WAVE VELOCITY IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS, MORTALITY AND DECLINE IN RENAL FUNCTION IN PATIENTS WITH TYPE 1 DIABETES

Tine Willum Hansen 1, Marie Frimodt-Møller 1, Simone Theilade 2, Nete Toftte 2, Tarun Veer Singh Ahluwalia 1, Peter Rossing 3
1Steno Diabetes Center Copenhagen, Gentofte, Denmark  
2Steno Diabetes Center Copenhagen, Gentofte, Denmark  
3Steno Diabetes Center Copenhagen, University of Copenhagen, Gentofte, Denmark

Purpose: The prognostic significance of carotid-femoral pulse wave velocity (cfPWV) remains to be determined in patients with type 1 diabetes (T1D). We investigated the predictive value of cfPWV for various endpoints in T1D.

Methods: At baseline, cfPWV was measured using the SphygmoCor device in 652 patients with T1D and various degrees of albuminuria. Endpoints were traced through National Registers and patient records and comprised: composite CVE, mortality, progression in albuminuria, and decline in estimated glomerular filtration rate (eGFR) >30%. Median follow-up ranged from 5.2 to 6.2 years. Slope estimates of eGFR and urinary albumin creatinine ratio (UACR) were calculated for a median of 5.5 years. Adjustment included sex, age, mean arterial pressure, LDL cholesterol, smoking, Hba1c, UACR and eGFR at baseline. Hazard ratios (HR) were calculated per 1 standard deviation (SD) increase in cfPWV.

Results: Of the 652 participants (56% male); mean ±SD age was 54 ± 13 years and cfPWV 10.5 ± 3.38 m/s2. After adjustment, higher cfPWV was significantly associated with all endpoints: composite CVE (n = 81; HR:1.31; p = 0.045); mortality (n = 48; HR:1.39; p = 0.033); progression in albuminuria (n = 31; HR:1.16; p = 0.012); and decline in eGFR >30% (n = 90; HR: 1.39; p < 0.015). Higher cfPWV was associated with a steeper decline in eGFR and a steeper increase in UACR after adjustments (p < 0.009).

Conclusions: In patients with T1D, higher arterial stiffness was consistently associated with a higher risk of CVE, mortality and decline in renal function, independent of other risk factors. Measurement of cfPWV may have a promising role in risk stratification in T1D.

Objectives: Accurate blood pressure (BP) measurement is critical for appropriate hypertension diagnosis and management. Aortic BP represents pressure loading on vital organs and this can be approximated using upper arm cuff BP.

With advancing age, cuff systolic BP (SBP) increases and diastolic BP (DBP) decreases (widening pulse pressure [PP]), but whether age may influence cuff BP compared with invasive BP is unknown and was the aim of this study.

Methods: Cuff BP was measured simultaneously, or near-simultaneously, with invasive aortic BP during catheterization in 1696 individuals within the INSPECT consortium (an international collaboration comprising data from 31 studies and 19 different cuff BP devices [17 oscillometric, 2 mercury sphygmomanometry]). Differences in cuff and invasive BP were assessed using mixed models.

Results: Subjects were aged 63.3 ± 10.6 years and 32% female. Cuff SBP overestimated invasive aortic SBP in those aged 40–49, but with increasing age there was a progressive increase in the underestimation of aortic SBP (Table). Conversely, cuff DBP systematically overestimated aortic DBP, increasing with age. Thus, there was a progressively higher error (underestimation) in cuff BP with older age. Adjusting models for sex, mean arterial pressure, heart rate and catheter type did not alter the findings, and no interactions between these parameters and age were found.

Conclusion: Cuff BP is progressively more biased with increasing age, exposing older people to greater chance for misdiagnosis of risk related to BP. The findings highlight the need to improve cuff BP methods to ensure all people receive appropriate diagnosis and management of hypertension.

<table>
<thead>
<tr>
<th>Age category</th>
<th>Cuff – invasive systolic BP (mmHg)</th>
<th>Cuff – invasive diastolic BP (mmHg)</th>
<th>Cuff – invasive pulse pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49 years</td>
<td>170</td>
<td>3.2 (0.5 to 6.6)</td>
<td>4.3 (2.3 to 6.5)</td>
</tr>
<tr>
<td>50–59 years</td>
<td>406</td>
<td>0.1 (2.2 to 2.9)</td>
<td>5.4 (3.7 to 7.4)</td>
</tr>
<tr>
<td>60–69 years</td>
<td>556</td>
<td>-0.3 (4.0 to 4.8)</td>
<td>4.9 (1.4 to 8.8)</td>
</tr>
<tr>
<td>70–79 years</td>
<td>458</td>
<td>-0.3 (5.5 to -1.1)</td>
<td>7.5 (10.5 to 10.2)</td>
</tr>
<tr>
<td>80+ years</td>
<td>98</td>
<td>4.5 (4.8 to -0.3)</td>
<td>9.9 (5.9 to 13.2)</td>
</tr>
</tbody>
</table>

Data are mean [95% confidence interval] BP; blood pressure.